Bruno Fant is the Chief Technology Officer at myNEO, a leader in Personalized Medicine and genomic-based drug discovery for oncology and immunology. He has been driving the development of the ImmunoEngine©, a cutting-edge platform for neoepitope selection in cancer patients, and overseeing technical enhancements. Bruno's role involves leveraging data from biopharma partners to enhance clinical outcomes and discover novel immunogenic targets, contributing to the advancement of personalized immunotherapies.